A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
A randomized, double-blind, positive controlled phase III study to evaluate the efficacy and safety of BPI-7711 capsule in locally advanced or recurrent/metastatic treatment-na√Øve non-small cell lung cancer patients with EGFR mutation
NSCLC
DRUG: BPI-7711|DRUG: Gefitinib|DRUG: Placebo Tablet|DRUG: Placebo capsule
Progression-free survival, Progression-free survival evaluated by Blinded Independent Center Review, up to approximately 16 months
Progression-free survival, Progression-free survival evaluated by investigators, up to approximately 16 months|Objective response rate, Objective response rate, up to approximately 16 months|Best objective response, Best objective response, up to approximately 16 months|Disease control rate, Disease control rate, up to approximately 16 months|Duration of response, Duration of response, up to approximately 16 months|Overall survival, Overall survival, up to approximately 30 months
This is a Phase III clinical study, which aims to compare the efficacy and safety of BPI-7711 capsule and gefitinib tablet in the treatment of initially-treated patients with locally advanced or recurrent metastatic with EGFR mutation.